GAMMA Investing
LCTX icon

GAMMA Investing’s Lineage Cell Therapeutics LCTX Stock Holding History

GAMMA Investing’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.17K Buy
+2,273
New +$2.51K ﹤0.01% 3930

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
HA
Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
EM
ELCO Management New York $213M AUM 25.23% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's LCTX Position: Q3 2026 in Review

GAMMA Investing opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 2,273 shares worth $2.17K. The stake represents ﹤0.01% of the portfolio and ranks #3930 among its holdings.

11 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • GAMMA Investing held 2,273 shares of Lineage Cell Therapeutics worth $2.17K as of Q3 2026.
  • Lineage Cell Therapeutics was a new GAMMA Investing position in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3930 holding.
  • 11 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.